Live
IlluminaThe Bull Case For Illumina (ILMN) Could Change Following Upgraded 2026 Outlook And Major Buyback - Learn Why - simplywall.stFierceBiotechFDA Commissioner Marty Makary to resign, capping turbulent tenure: reportFierceBiotechKyverna begins rolling submission for autoimmune CAR-T as FDA requests more natural history analysisClinical OMICsLow‑Dose Digoxin Shows Benefit in Heart Failure TreatmentClinical OMICsAntibody Promotes Nerve Regeneration in Spinal Cord Injury PatientsClinical OMICsSingle Procedure Reduces Colorectal Cancer Risk Decades Later10x Genomics News10x Genomics settles suit with rival and targets DNA sequencing startup - Life Sciences Intellectual Property ReviewClinical OMICsFirst Clinical Trial for a GLP-1 Gene Therapy Greenlit in EuropeBioPharma DiveFDA chief Marty Makary resigns from agency, ending tumultuous tenureEndpoints NewsEU reaches provisional deal on Critical Medicines ActEndpoints NewsFDA Commissioner Makary to resign, source saysEndpoints NewsIran war disruptions begin to emerge upstream of the pharma supply chain
Illumina Mar 28, 2026

Exchange Traded Concepts LLC Lowers Stock Holdings in Illumina, Inc. $ILMN - MarketBeat

Exchange Traded Concepts LLC Lowers Stock Holdings in Illumina, Inc. $ILMN - MarketBeat

Original
Body unavailable. Use the original source.